Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Biomarker Development for Postoperative Cognitive Impairment in the Elderly

BioCog

Postoperative delirium (POD) is characterized by the progressive deterioration of sensory/cognitive function after surgery with incidences of up to 30-80%. It is frequently followed by postoperative cognitive dysfunction (POCD) which tends to persist over time. In elderly patients, POCD resembles chronic dementia and appears to accelerate the...

Funding Programme
Start Date
End Date
Total Funding
€ 7 743 063
European Countries Involved

Biomarkers for Alzheimer’s disease and Parkinson’s disease.

BIOMARKAPD

Neurodegenerative disorders, represented mostly by Alzheimer's disease (AD) and Parkinson's disease (PD), are characterised by progressive neuronal impairment and death. In spite of the brain's known capacity for regeneration, lost neurons generally cannot be replaced. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to...

Funding Programme
Start Date
End Date
Total Funding
€ 449 066

Blood Biomarker-based Diagnostic Tools for Early Stage Alzheimer’s Disease

BBDiag

Alzheimer’s disease (AD) affects more than 7 million people in Europe and this figure is expected to double every 20 years. Despite intensive efforts, no disease-modifying treatments or preventive strategies are available. The lack of specific, sensitive and minimally invasive diagnostics to identify people with early-stage AD to be included in...

Funding Programme
Start Date
End Date
Total Funding
€ 3 465 708
European Countries Involved

blood Proteins for early Discrimination of dEmentias

bPRIDE

Dementia is a group of disorders characterized by severe memory loss ultimately impairing daily life activities. Major forms are Alzheimer’s disease, Lewy body dementia, and frontotemporal dementia. Each dementia type is caused by different biological factors and therefore requires a specific treatment targeting these factors. To develop effective...

Funding Programme
Start Date
End Date
Total Funding
€ 1 800 000
European Countries Involved

Brain barriers training

BtRAIN

The brain barriers function to protect the central nervous system (CNS) from neurotoxic compounds. By the same traits they unfortunately block delivery of drugs to the CNS thus hindering proper diagnosis and effective treatment of neurological disorders including Alzheimer’s disease and multiple sclerosis. The unusual complexity of the brain...

Funding Programme
Start Date
End Date
Total Funding
€ 3 067 402

Brain image processing with Alpha-Stable distributions. Applications to intensity normalization,segmentation and diagnosis of Parkinsonian syndrome and Alzheimer's disease

ALPHA-BRAIN-IMAGING

In this project, D. Salas-Gonzalez proposes to develop brain image processing with alpha-stable distributions with applications to intensity normalization, segmentation and diagnosis of Parkinsonian syndrome and Alzheimer's disease. The expected results of this interdisciplinary project will definitely have applications and impact in the European...

Funding Programme
Start Date
End Date
Total Funding
€ 223 778
European Countries Involved

BRain Imaging, cognition, Dementia and next generation GEnomics: a Transdisciplinary approach to search for risk and protective factors of neurodegenerative disease

BRIDGET

Establishing efficient prevention strategies for dementia and Alzheimer's disease is a major health priority. Since the cascade of events leading to Alzheimer's disease begins many years before the disease is detected, efficient prevention should be initiated early.

This requires identifying individuals in the general population who are at high...

Funding Programme
Start Date
End Date
Total Funding
€ 3 111 460
European Countries Involved

Bridging the world of fungi and dementia

PROFITS

Alzheimer’s disease is the most common form of dementia which seriously interferes with the daily life of millions of people. People suffering from Alzheimer’s disease show the accumulation of two misfolded proteins in the nerve cells of their brains – amyloid plaques and tau tangles. Although many aspects of the Alzheimer’s disease pattern are...

Funding Programme
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved

Building Next-Generation Brain/Neural-Machine Interfaces For Restoration of Brain Functions

NGBMI

Today, five out of ten diseases worldwide resulting in long-term disability are related to the central nervous system. Due to the immense complexity and inter-individual variability of the human mind and brain there are still no effective and side effect free treatment options for many serious neuropsychiatric disorders, such as major depression...

Funding Programme
Start Date
End Date
Total Funding
€ 1 498 125
European Countries Involved

C9orf72 repeat expansion in FTD/ALS - from mechanisms to therapeutic approaches

DPR-MODELS

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are fatal neurodegenerative diseases with overlapping genetics and pathology. The most common known cause is expansion of a GGGGCC repeat in the first intron of the gene C9orf72. I discovered that the repeat region is translated in all three reading frames into aggregating...

Funding Programme
Start Date
End Date
Total Funding
€ 1 991 000
European Countries Involved

Cell type-specific molecular analysis of epigenetic changes and transposable element derepression in Alzheimer's disease progression

CTS-TEs-ADprogress

Alzheimer’s disease (AD) is a major contributor to disease burden and healthcare costs worldwide. AD is usually diagnosed once symptoms like memory impairment become evident. However, at this point typical AD pathology such as Aβ plaques and cell death is already widespread, suggesting that molecular changes have occurred decades before symptom...

Funding Programme
Start Date
End Date
Total Funding
€ 174 806
European Countries Involved

Cellular determinants of neuronal plasticity
on the level of single synapses in vivo

InVivoSynapse

The search for the fundamental mechanisms of learning and experience-dependent memory formation in the brain has long been a central quest in neuroscience. The neocortex is a particularly relevant region for plasticity because it is involved in sensory, motor, and cognitive tasks with strong learning components. However, despite many years of...

Funding Programme
Start Date
End Date
Total Funding
€ 2 404 800
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).